Myeloproliferative Neoplasms Treatment Market Size to Exceed USD 12.69 Bn by 2032

The Myeloproliferative Neoplasms Treatment Market, estimated at USD 9.71 Bn in 2025, is expected to exhibit a CAGR of 3.9% and reach USD 12.69 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Key market players are focusing on adopting growth strategies such as research and development, which will drive the global myeloproliferative neoplasms treatment market growth. For instance, on June 10, 2025, Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, presented updated positive data from its ongoing global phase 2 clinical study evaluating bomedemstat in patients with essential thrombocythemia (ET). The data presented in a poster session during the 30th European Hematology Association Annual Meeting and Congress (EHA) took place on June 9, 2025.

Global Myeloproliferative Neoplasms Treatement Market – Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of things from one place to another.

COVID-19 had a negetive impact on the global myeloproliferative neoplasms treatment market. For instance, according to the data published by the World Health Orgnization in March 22, 2025, the covid-19 pandemic has made the challenges that people living with non-communicable diseases face in accessing essential medicines. Moreove, many had their treatment disrupted, which could lead to serious helath consequences.

Global Surgical Equipments Market: Key Developments

On November 21, 2025, Merck, a pharmaceutical company headquartered in New, Jersey, U.S. and Imago BioSciences, Inc. a clinical stage biopharmaceutical company, announced that the companies had entered into a  definitive agreement under which Merck, through a subsidiary, will acquire Imago for US$ 36.00 per share in cash for an approximately total equity value of US$ 1.35 billion. Imago is a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases. Imago company’s lead candidate bomedemstat (IMG-7289), an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor, is currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia (ET), myelofibrosis (MF), and polycythemia vera (PV)

On July 1, 2025, GSK plc, a multinational pharmaceutical and biotechnology company with global headquarters in London, announced that it has completed the acquisition of Sierra Oncology, Inc., a California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer. the acquisition of Sierra Oncology includes momelotinib, a late-stage potential new medicine with a unique dual mechanism of action that may address the critical unmet medical needs of myelofibrosis patients with anaemia.

Browse 36 Market Data Tables and 26 Figures spread through 180 Pages and in-depth TOC on “Global Myeloproliferative Neoplasms Treatment Market”- Forecast to 2032, Global Myeloproliferative Neoplasms Treatment Market, By Disease Type (Essential Thrombocythemia (ET), Myelofibrosis (MF), and Polycythemia Vera (PV)), By Drug Class (Tyrosine Kinase Inhibitors, Janus kinase inhibitors (JAKi), Antimetabolites, and Others (alkylating agents, etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies),  and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/myeloproliferative-neoplasms-treatment-market-930

Key Takeaways of the Global Myeloproliferative Neoplasms Treatment Market:

• The global myeloproliferative neoplasms treatment market is expected to exhibit a CAGR of 3.9% during the forecast period. The increasing prevalence of myeloproliferative neoplasms offers lucrative growth opportunities for players in the global myeloproliferative neoplasms treatment market.
• Among disease type, the Essential Thrombocythemia (ET) segment is expected to hold a dominant position in the global myeloproliferative neoplasms treatment market during the forecast period and this is attributed to the increasing prevalence of Essential Thrombocythemia (ET). For instance, according to data published by the Orphanet, the prevalence of Essential Thrombocythemia (ET) is estimated at 1/4,200 in the U.S. and is reported 1/3,333 in Sweden. Median age at diagnosis is 60-65 years, but the disease may occur at any age, with another peak in incidence in younger women. The female to male ratio is about 2:1.
• Among region, North America is expected to be the dominant region in the global myeloproliferative neoplasms treatment market, owing to increasing research and development activities in the region. Fo instance, in December 10, 2025, Incyte, a pharmaceutical company headquartered in Delaware, U.S., announced new data from two of its LIMBER (Leadership In MPNs and GVHD BEyond Ruxolitinib) trials evaluating monotherapy and combination strategies using ruxolitinib (Jakafi) with parsaclisib, its investigational phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, and INCB00928 (zilurgisertib), its activin receptor-like kinase (ALK2) inhibitor, in patients with myelofibrosis (MF).
• Major players operating in the global myeloproliferative neoplasms treatment are Novartis AG, PharmaEssentia Corporation, Bristol Myers Squibb, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Incyte, Johnson & Johnson, Teva Pharmaceutical Industries Ltd, Hoffmann-La Roche AG, Gamida Cell, Sierra Oncology, Inc, CTI BioPharma Corp, Imago BioSciences, AbbVie Inc, and Constellation Pharmaceuticals